Crohn's disease of the esophagus: report of a case.
We report herein the case of a 27-year-old man with Crohn's disease of the esophagus. The patient presented with large ulcers in the esophagus for which treatment based on a diagnosis of reflux esophagitis was commenced. Although his symptoms were initially resolved, the ulcers did not improve and he was readmitted to hospital 3 months later for progressive heartburn. An esophagoscopy revealed large ulcers in the esophagus, and a colonoscopy revealed a longitudinal ulcer in the terminal ileum. Histological examination of specimens from the terminal ileum showed severe inflammation without granuloma formation, which led to a diagnosis of Crohn's disease. The oral administration of prednisolone and salazosulfapyridine controlled his symptoms and the esophageal ulcers were observed to be healing 2 weeks after this treatment was initiated. A review of the English literature revealed only 77 cases of this disease. Isolated esophageal lesions were reported in ten patients (13.0%), none of which were able to be diagnosed as Crohn's disease preoperatively. Ileocolic lesions developed after esophageal lesions in only five patients (6.5%) including ours. In the remaining 62 patients (80.5%), ileocolic lesions had existed synchronous with or prior to the esophageal lesions. This suggests that ileocolic lesions may often coexist in Crohn's patients with esophageal lesions, and that examination of the terminal ileum must be performed to confirm a diagnosis of Crohn's disease of the esophagus.
Ohta
M
M
Department of Surgery II, Hamamatsu University School of Medicine, Japan.
Konno
H
H
Kamiya
K
K
Suwa
D
D
Baba
M
M
Tanaka
T
T
Nakamura
T
T
Nishino
N
N
Sugimura
H
H
Nakamura
S
S
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D003424:Crohn Disease / Q000188:drug therapy / Q000473:pathology*; D004935:Esophageal Diseases / Q000188:drug therapy / Q000473:pathology*; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D007077:Ileal Diseases / Q000473:pathology*; D008297:Male; D011239:Prednisolone / Q000627:therapeutic use; D012460:Sulfasalazine / Q000627:therapeutic use; D014456:Ulcer / Q000473:pathology
D000893:Anti-Inflammatory Agents; D005765:Gastrointestinal Agents; D012460:Sulfasalazine; D011239:Prednisolone